Commodore Capital LP Reports New 9.9% Stake in Inhibikase Therapeutics, Inc. (IKT)

On May 15, 2026, Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, filed a Schedule 13G/A reporting a new 9.9% stake in Inhibikase Therapeutics, Inc. (IKT). The reporting group beneficially owns 14,054,940 shares of Common Stock as of March 31, 2026. This position is comprised of 5,397,488 direct shares, 5,290,799 shares underlying Tranche 1 Warrants, and 3,366,653 shares underlying Tranche 2 Warrants. The filing notes that additional Tranche 2 Warrants (6,362,736 shares) and Pre-Funded Warrants (16,133,234 shares) are currently excluded from the beneficial ownership total due to a 9.99% beneficial ownership limitation. Commodore Capital LP serves as the investment manager to Commodore Capital Master LP, with Michael Kramarz and Robert Egen Atkinson exercising investment discretion as managing partners. The filing indicates the acquisition was made for investment purposes in the ordinary course of business, without the intent to influence control of the issuer.